3. Why Lupin
ī Lupin is the 4th
largest player in Indian pharmaceuticals industry.
ī It has emerged as an out performer in the Pharma sector.
ī Its Stock counted among frontline farm stock and considered for
the long term buy.
ī The company over the year has grown to be one of the top ten
generic company in the USA, Japan & South African market.
4. About Lupin
ī Lupin Limited is an innovation led transnational pharmaceutical
company producing a wide range of quality, affordable generic and
branded formulations.
ī Lupin first gained recognition when it became one of the world's
largest manufacturers of Tuberculosis drugs.
ī Lupin has emerged as the 4th largest and the fastest growing Top 5
company in the U.S.A.
ī Began Operations : 1968
5. About Lupin
Board of Directors
âĸ Dr Desh Bandhu Gupta - Chairman
âĸ Dr Kamal K Sharma - Managing Director
âĸ Mrs M. D. Gupta - Executive Director
âĸ Mrs Vinita Gupta - Director
âĸ Mr Nilesh Gupta - Executive Director
âĸ Dr Vijay Kelkar - Director
âĸ Mr Richard Zahn - Director
âĸ Mr R. A. Shah â Director
6. 6
Lupinâs FacilitiesLupinâs Facilities
LOCATION PRODUCTS APPROVALS
Mandideep,
Madhya
Pradesh
Cephalosporins
Prils
WHO, US
FDA, UK
Tarapur,
Maharashtra
Rifampicin
Lovastatin
US FDA,
WHO
Ankleshwar,
Gujarat
Ethambutol
Intermediates
WHO
Aurangabad,
Maharashtra
Anti TB
Lisinopril
WHO, MSF,
Verna,
Goa
Non-
cephalosporin
Oral FD
US FDA,
Jammu,
J&K
Oral FD FDA
Indore,
Madhya
Pradesh
API
FD
-
Baroda,
Gujarat
CRAMS -
Pune,
Maharashtra
R&D
Goa
Pune
arapur
nkleshwar
Mandideep
Aurangabad
Jammu
Mumbai
Indore
Baroda
Head Office:- Mumbai, Maharashtra
7. Vision Of The Company
An Innovation Led,
Transnational
Pharmaceutical Company.
8. Mision Of The Company
Our mission is to become a
transnational pharmaceutical company
through the development and
introduction of a wide portfolio of
branded and generic products in key
markets.
9. Values Of The Company
īSuperior Performance
īEntrepreneurship
īCustomer Orientation
īWorking Together
īRespect for People
īIntegrity
10. History & Milestone Of Lupin
ī1968: Lupin started business.
ī1972: Lupin Laboratories Pvt. Ltd was incorporated.
ī1980: Lupin Started a formulations plant and an R&D center at
Aurangabad (Maharastra).
ī2001: State-of-the-art R&D Centre at Pune was Started.
11. History & Milestone Of Lupin
ī2004 : WHO approval was received for State of the art
formulation Plants at Goa and Aurangabad.
ī2009 : Lupin acquired majority stake in Multicare
Pharmaceuticals Philippines Inc.
ī2011: Lupin Acquires I'rom Pharmaceuticals through its Japanese
Subsidiary.
13. Awards-Accolades Of Lupin
ī2009 :International Excellence Award by Institute of Economic
Studies.
ī2010 : Best Drug Development Company, Asia' by The New
Economy Pharmaceutical & Healthcare Awards.
ī2010: Lupin wins 'The Most Promising Entrant into the Big
League' by CNBC India Business Leader Awards.
ī2011: Lupin ranked amongst India's Top 3 'Best Companies to
Work For' in Healthcare and Pharma Sector.
ī2012: Mrs. Vinita Gupta won the Business Today '30 Most
Powerful Women in Business' award.
17. STP Analysis
Positioning
īIt is innovation led pharmaceutical company, which specializes in
generic, API & branded formulations for developed &
developing world.
20. Product
ī Formulation : This is the production of capsules, tablets and
syrup with the help of APIâs. A branch which is producing
APIâs will send this for formulation.
22. Product
īAPIâs : This is the active pharmaceutical
ingredient. This is in the form of powder and
this is generally using in the formulation of
medicine. It is the kind of production .
24. Place
ī Lupin has created strong foothold in the advanced markets
of USA , Europe, Japan , Australia and emerging markets of
India and some of the other Rest of the world countries.
.
25. Price
ī Initially the company adopted Cost based pricing strategy but after
new Pharma pricing policy, it has changed its pricing policy.
ī New Pricing Policy
ī New pricing policy is good for the people of India who can buy essential
drugs at cheaper prices and at the same time it is less taxing for the
Pharma companies.
26. Promotion
ī Influencing the physician is key to pharmaceutical sales.
Physicians are the most important players in pharmaceutical
sales.
ī Eli Lilly India (Lilly) and Lupin ltd announced that they
have entered into strategic collaboration to promote and
distribute Lillyâs Hum insulin range of products.
30. PESTAL Analysis
Political
īGovernments have a responsibility to take all necessary measures
to ensure that much-needed new medicines are developed,
become available and are accessible.
31. PESTAL Analysis
Economic
ī Global economic crisis.
ī Reduction in individual income.
ī The economic crisis pressure are seeing an increased growth in
strategic buying groups who are forcing down prices.
33. PESTAL Analysis
Technological
The technological advancement creates new business prospects
both in terms of new therapy systems and service provisions. The
online opportunities will see the growth in:
īCustomized treatment
īSocial media for health care
īDirect to patient advertising
īDirect to patient communication
36. Porterâs five forces Analysis
Power of Buyers
ī Generic (low cost versions of the branded drugs) drugs offer
cost-effectives to the innovator drugs and thus offer significant
savings for buyers.
ī The bargaining power of buyers is high.
37. Porterâs five forces Analysis
Power of suppliers
ī The barging power is high for API companies with difficult to
manufacture products. These companies command premium
prices. However majority of API suppliers have low barging
power since they produce products which are simple to
manufacture or commoditized.
ī Thus bargaining power of suppliers as a whole is Medium.
38. Porterâs five forces Analysis
Competitive Rivalry
ī The growth opportunities for Pharma companies are expected to
grow manifold in the next few years with many drugs going off
patent in the US and emerging countries coming into focus.
ī The competitive rivalry is high.
39. Porterâs five forces Analysis
Availability of substitutes
ī The threat of substitution is higher in unbranded markets
where one generic can be substituted by another by the
pharmacists.
ī The threat of substitute is high.
40. Porterâs five forces Analysis
Entry barriers
ī Entry barriers in the emerging markets are high due to its branded
nature.
ī However the companies require extensive legal knowledge
combined with ability to develop the product earlier than
competition, this is possible for only a few top companies.
42. Company
Market share of Pharma
company in India
Cipla 5.6
Ranbaxy 4.76
Dr. Reddy's laboratory 4.47
Sun Pharma 4.03
Lupin 2.73
Cadila Healthcare 2.07
Glaxosmithkline Pharmaceuticals 1.79
Matrix Laboratories Ltd. 1.6
Ipca Laboratories Ltd. 1.36
Other 1.29
44. SWOT analysis
īWorld wide leader in Anti TB drugs .
īIn the US and Japanese market it is the largest
generic player.
ī Wide global footprint as it is present in over
70 countries
45. SWOT analysis
ī High dependence on global formulation business
with 84% revenue coming from US market.
ī It operates in low growth segments such CNS,
respiratory diseases
46. SWOT analysis
ī Increased health awareness.
ī Emerging technological trends in
drug delivery.
ī Increasing prevalence of TB in
developing countries .
47. SWOT analysis
ī Price regulation by government reduce the pricing
ability of company.
ī With around 20000 unorganized and 300 large
organized player makes Indian Pharma industry
highly competitive .
48. 48
Lupinâs Business ModelLupinâs Business Model
Technology
âĸR&D
âĸBiotechnology
âĸChemical & pharma
engineering
Alliances
âĸIn-Licensing
âĸLong term partnership with
customers
Sustainable Earnings
Accelerated Growth
Fulfilling Stakeholder
Aspirations
Sustainable Earnings
Accelerated Growth
Fulfilling Stakeholder
Aspirations
Markets
âĸAdvanced Markets â
Exponential Growth
âĸGeographical
Expansion â Emerging
Markets
âĸ Enhanced Market
Penetration & New
Therapies
Generics Formulation API
Acquisitions
âĸMarkets
âĸTherapies
âĸTechnology
54. PARTICULARS Mar.12
RS. Cr
Mar.11
Rs . Cr
Sources Of Funds
Equity Share Capital 89.33 89.24
Reserves 3,995.85 3,243.35
Net worth 4,012.89 3,281.08
Secured Loans 764.48 784.13
Unsecured Loans 716.39 378.28
Total Debt 1,480.87 1,162.41
Total Liabilities 5,566.05 4,495.00
Application Of Funds
Gross Block 3,985.52 2,964.34
Less: Accum. Depreciation 1,232.78 907.51
Net Block 2,752.74 2,056.83
Capital Work in Progress 440.64 531.22
55. PARTICULARS Mar.12 Mar.11
Investments 2.80 3.15
CURRENT ASSETS
Inventories 1,732.67 1,199.96
Sundry Debtors 1,731.81 1,255.82
Cash and Bank Balance 402.47 171.29
Total Current Assets 3,866.95 2,627.07
Loans and Advances 870.89 683.14
Fixed Deposits 0.00 248.83
Total CA, Loans & Advances 4,737.84 3,559.04
Current Liabilities 2,039.29 1,383.43
Provisions 328.68 271.81
Total CL & Provisions 2,367.97 1,655.24
Net Current Assets 2,369.87 1,903.80
Total Assets 5,566.05 4,495.00
62. COMPANY
NAME
LAST PRICE NET SALES TOTAL ASSETS
SUN PHARMA 678.50 4015.56 8094.90
CIPLA 378.10 6977.50 7520.84
DR. REDDYS
LAB
1722.40 6686.30 8251.20
LUPIN 561.70 5364.37 4703.07
RANBAXY LABS 511.60 7686.59 6123.38
63. âHuman Resources are something above each
measurement. The capacity of these resources can be
extended indefinitely when each person begin to
think.â
68. Lupin is using three different medium for selecting the right talent:
īManagement Trainee Programme
īYoung Leaders Programme
īAdvertisement
69. Learning and Development
ī Lupin has instituted various programs aimed at developing
leadership qualities for first line supervisors, mid-sized team
leaders or large function heads.
ī They have developed specific programs in order to groom this
talent pool on individual basis in 3 areas:
âĸ Education
âĸ Training & Development
âĸ Job rotation / exposure
70. Programmer For New Joiners and First-line Supervisors
ī Udbhav
ī The Iceberg
ī Leader Plus
ī Buddy
71. For Managers:
ī AMEX (Accelerating Managerial Excellence)
ī Manufacturing Business Leadership Programme
ī Executive Coaching For Senior Management
73. ī Employee appraisals are a balancing act between the
expectations of employees and the management's
perception of the employee's contribution to business
goals.
ī The Company use Management By Objective Method for
Performance Appraisal.
ī It is a developmental aspect as it involves employee
training for right fit.
74. Need of HR Specialized employees
Issue:
Higher Education Aspirations.
Solution:
Introduction of the PhD Program at the Lupin Research Park.
75. Whistle Blowing Policy
īWhistleblowing encourages and enables employees to raise
serious concerns within the Council rather than overlooking a
problem or 'blowing the whistle' outside.
īTransparency helps Companies to redefine processes and
make improvements.
80. Milestones of LHWRF
ī Won the FICCI Ladies Organization Award for Women
Welfare.
ī Third Dalmia Environment Award for best water
management practices.
ī Award for outstanding achievement in rural development.